secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001493152-25-019112
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics appoints Kameel Farag as interim CFO
-------------------------------------------------------

- Kameel Farag appointed interim CFO effective October 22, 2025; succeeds Torsten Hombeck.
- Compensation: $18,000/month cash + $12,000 in RSUs for Oct-Dec 2025; increases in Jan-Feb 2026.
- Consultant also entitled to 1.0% of capital raise proceeds up to $200,000 cap (0.5% after term).
- Consulting agreement runs through February 16, 2026, with possible month-to-month extensions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225019112/0001493152-25-019112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315225019112/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer